早期三阴性乳腺癌新辅助免疫治疗联合化疗的研究进展

Research progress of neoadjuvant immunotherapy combined with chemotherapy for early triple-negative breast cancer

摘要: 三阴性乳腺癌（triple-negative breast cancer，TNBC）占乳腺癌的15%～20%，具有侵袭性强，预后差的特点，且以紫杉烷类、蒽环类及环磷酰胺为基础的新辅助化疗方案疗效与患者长期生存获益仍不尽人意。TNBC因免疫原性较强，免疫治疗可使其有较大的疗效获益。近年来，早期TNBC患者新辅助免疫治疗联合化疗的研究引起人们广泛关注，本文将就早期TNBC新辅助免疫治疗联合化疗的治疗策略、疗效与安全性，及影响其疗效因素的研究进行综述。

Abstract: Triple-negative breast cancer (TNBC) accounts for 15%-20% of breast cancer and is characterized by high aggression and poor prognosis. The efficacy and long-term survival benefits of neoadjuvant chemotherapy regimens based on taxanes, anthracyclines, and cyclophosphamides remain unsatisfactory. Because of the strong immunogenicity of TNBC, immunotherapy could confer great benefits. In recent years, the study of neoadjuvant immunotherapy combined with chemotherapy for patients with early TNBC has attracted widespread attention. To summarize the efficacy and safety of treatment strategies in previous studies and explore factors affecting efficacy, the current study reviewed the research progress of neoadjuvant immunotherapy combined with chemotherapy for early TNBC.